Skip to content. | Skip to navigation

Personal tools

Yuzhuo Wang, Ph.D

Distinguished Scientist



Publications | Books and Chapters 

Accepted Article



1. Lin D, Wang X, Choi S, Ci X, Dong X, Wang YZ. Immune phenotypes of prostate cancer cells: evidence of EIT?  Asian Journal of Urology.  3(4): 195-202, 2016.

2. Ricke W.A., Williams K., Palapattu G., Wang Y.Z., and Cunha GR. Hormonal carcinogenesis: Roles of estrogens. In The Molecular Basis of Human Cancer (Coleman, W. B., ed) Vol. Part V, Springer International Publishing, pp 307-322, 2016

3. Davies AH, Wang YZ, Zoubeidi A. Patient-Derived Xenografts: A Platform for Accelerating Translational Research in Prostate Cancer.  Molecular and Cellular Endocrinology (In Press) IF 3.611.

4. Somasekharan SP, El-Naggar, Sorensen P, Wang YZ and Cheng H. An Aqueous Extract of Marine Microalgae Exhibits Anti-Metastatic Activity through Preferential Killing of Suspended Cancer Cells and Anti-Colony Forming Activity. Evidence-Based Complementary and Alternative Medicine. IF 1.931

5. Bishop J, Thaper D, Vahid S, Davies A,  Ketola K,  Kuruma H, Jama R, Nip K, Johnson F, Wyatt A, Fazli L, Gleave M, Lin D, Rubin M, Collins C, Wang YZ, Beltran H, and Zoubeidi A. The master neural transcription factor BRN2 is an androgen receptor suppressed driver of neuroendocrine differentiation in prostate cancer. Cancer Discovery DOI: 10.1158/2159-8290.CD-15-1263 Published 26 October 2016 IF: 19

6. Luk I, Shrestha R, Xue H ,Wang Y, Zhang F, Lin D, Haegert A, Wu R, Dong X, Collins C, Zoubeidi A, Gleave M, Gout PW, Wang YZ. BIRC6-targeting as potential therapy for advanced, enzalutamide-resistant prostate cancer. Clin. Cancer Research 2016 Sep 23. pii: clincanres.0718.2016. [Epub ahead of print] IF 8.722.

7. Sun X, Clermont PL, Jiao W, Helgason CD, Gout PW, Wang Y, Qu S. Elevated expression of the centromere protein-A(CENP-A)-encoding gene as a prognostic and predictive biomarker in human cancers. Int J Cancer. 2016 Aug 15;139(4):899-907. PMID: 27062469.

8. Wang Y, Wang JX, Xue H, Lin D, Dong X, Gout PW, Gao X, Pang J. Subrenal capsule grafting technology in human cancer modeling and translational cancer research. Differentiation. 2016 Apr-Jun;91(4-5):15-9. PMID: 26547391.

9. Choi SY, Xue H, Wu R, Fazli L, Lin D, Collins CC, Gleave ME, Gout PW, Wang Y. The MCT4 Gene: A Novel, Potential Target for Therapy of Advanced Prostate Cancer. Clin Cancer Res. 2016 Jun 1;22(11):2721-33. PMID: 26755530.

10. Li Y, Donmez N, Sahinalp C, Xie N, Wang Y, Xue H,  Mo F, Beltran H, Gleave M, Wang  YZ, Collins C, Dong X. SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition. European Urology, . 2016 May 11. pii: S0302-2838(16)30138-5. doi: 10.1016/j.eururo.2016.04.028. [Epub ahead of print] IF: 14.976.

4. Crea F, Quagliata L, Michael A, Liu HH, Frumento P, Azad AA, Xue H, Pikor L, Watahiki A, Morant R, Eppenberger-Castori S, Wang Y, Parolia A, Lennox KA, Lam WL, Gleave M, Chi KN, Pandha H, Wang Y, Helgason CD. Integrated analysis of the prostate cancer small-nucleolar transcriptome reveals SNORA55 as a driver of prostate cancer progression. Mol Oncol. 2016 May;10(5):693-703. PMID: 26809501.

5. Chapuy B, Cheng H, Watahiki A, Ducar MD, Tan Y, Chen L, Roemer MG, Ouyang J, Christie AL, Zhang L, Gusenleitner D, Abo RP, Farinha P, von Bonin F, Thorner AR, Sun HH, Gascoyne RD, Pinkus GS, van Hummelen P, Wulf GG, Aster JC, Weinstock DM, Monti S, Rodig SJ, Wang Y, Shipp MA. Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease. Blood. 2016 May 5;127(18):2203-13. PMID: 26773040.

6. Crea F, Venalainen E, Ci X, Cheng H, Pikor L, Parolia A, Xue H, Nur Saidy NR, Lin D, Lam W, Collins C, Wang Y. The role of epigenetics and long noncoding RNA MIAT in neuroendocrine prostate cancer. Epigenomics. 2016 May;8(5):721-31. PMID: 27096814.

7. Clermont PL, Crea F, Chiang YT, Lin D, Zhang A, Wang JZ, Parolia A, Wu R, Xue H, Wang Y, Ding J, Thu KL, Lam WL, Shah SP, Collins CC, Wang Y, Helgason CD. Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer. Clin Epigenetics. 2016 Feb 12. PMID: 26877821

8. Hao J, Chiang YT, Gout PW, Wang Y. Elevated XPO6 expression as a potential prognostic biomarker for prostate cancer recurrence. Front Biosci (Schol Ed). 2016 Jan 1;8:44-55. PMID: 26709895.



1. Fornaro L, Faviana P, De Gregorio V, Vivaldi C, Paolicchi E, Masi G, Loupakis F, Sensi E, Lupi C, Fontanini G, Wang Y, Danesi R, Falcone A, Crea F. Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer. BMC Cancer. 2015 Nov 9;15:874. PMID: 26553291

2. Jäger W, Xue H, Hayashi T, Janssen C, Awrey S, Wyatt AW, Anderson S, Moskalev I, Haegert A, Alshalalfa M, Erho N, Davicioni E, Fazli L, Li E, Collins C, Wang Y, Black PC. Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies. Oncotarget. 2015 Aug 28;6(25):21522-32. PMID: 26041878

3. Akamatsu S, Wyatt AW, Lin D, Lysakowski S, Zhang F, Kim S, Tse C, Wang K, Mo F, Haegert A, Brahmbhatt S, Bell R, Adomat H, Kawai Y, Xue H, Dong X, Fazli L, Tsai H, Lotan TL, Kossai M, Mosquera JM, Rubin MA, Beltran H, Zoubeidi A, Wang Y, Gleave ME, Collins CC. The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer. Cell Rep. 2015 Aug 11;12(6):922-36. PMID: 26235627.

4. Crea F, Di Paolo A, Liu HH, Polillo M, Clermont PL, Guerrini F, Ciabatti E, Ricci F, Baratè C, Fontanelli G, Barsotti S, Morganti R, Danesi R, Wang Y, Petrini M, Galimberti S, Helgason CD. Polycomb genes are associated with response to imatinib in chronic myeloid leukemia. Epigenomics. 2015 Aug;7(5):757-65. PMID: 26343356

5. Beltran H, Eng K, Mosquera JM, Sigaras A, Romanel A, Rennert H, Kossai M, Pauli C, Faltas B, Fontugne J, Park K, Banfelder J, Prandi D, Madhukar N, Zhang T, Padilla J, Greco N, McNary TJ, Herrscher E, Wilkes D, MacDonald TY, Xue H, Vacic V, Emde AK, Oschwald D, Tan AY, Chen Z, Collins C, Gleave ME, Wang Y, Chakravarty D, Schiffman M, Kim R, Campagne F, Robinson BD, Nanus DM, Tagawa ST, Xiang JZ, Smogorzewska A, Demichelis F, Rickman DS, Sboner A, Elemento O, Rubin MA. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. JAMA Oncol. 2015 Jul;1(4):466-74. PMID: 26181256

6. Lin D, Dong X, Wang K, Wyatt A, Crea F,  Xue H, Wang Y, Wu R, Bell R, Haegert A, Brahmbhatt S, Hurtado-Coll A, Gout PW, Fazli L, Gleave M, Collins C, Wang YZ. Identification of DEK as a potential therapeutic target for neuroendocrine prostate cancer. Oncotarget. 2015;6(3):1806-20..PMID: 25544761. IF 6.67

7. Xie N, Cheng H, Lin D, Liu L L, Yang O, Fazli L, Jia L, Gleave M, Wang YZ, Rennie P, Dong X. The Expression of Glucocorticoid Receptor is Negatively Regulated by Active Androgen Receptor Signaling in Prostate Tumors. International Journal of Cancer 2015 Feb 15;136(4):E27-38. (Cited by 1).    IF 5.007

8. Yoshi Y,  Loriot Y, Beraldi E, Zhang F, Wyatt A, Mo F, Zhou, T, Kim Y, Monia B, Macleod R, Fazli L, Wang YZ, Collins C, Zoubeidi A, Gleave M. Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and its Splice Variants Suppress Enzalutamide Resistant Prostate Cancer Cell Growth. Clinical Cancer Research 2015 Jan 29. pii: clincanres.1108.2014. [Epub ahead of print]. IF 8.193

9. Somasekharan SP, EI-Naggar A, Cheng H, Leprivier G, Hajee S, Grunewald T, Ng T, Delattre O, Evdokimova V, Wang YZ, Gleave M, and Poul H Sorensen PH. YB-1 regulates stress granule formation and tumor progression by translationally activating G3BP1. J Cell Biology Mar 23. pii: jcb.201411047. [Epub ahead of print].  IF 9.6.

10. Crea F, Saidy NRN, Collins C, Wang YZ. The epigenetic/non-coding origin of tumour dormancy. Trends Mol Med 2015 Mar 11. pii: S1471-4914.  IF 10.11.

11. Parolia A, Crea F, Xue H, Wang Y, Mo F, Ramnarine VR, Liu H, Lin D, Saidy R, Clermont PL, Cheng H, Collins C, Wang YZ, Helgason CD. The long non-coding RNA PCGEM1 is regulated by androgen receptor activity in vivo. Molecular Cancer 2015, 14:46  doi:10.1186/s12943-015-0314-4. IF 5.4. 

12. Azad AA, Volik SV, Wyatt AW, Haegert A, Le Bihan S, Bell RH, Anderson S, McConeghy B, Shukin R, Bazov J, Youngren J, Paris PL, Thomas GV, Small EJ, Wang YZ, Gleave ME, Collins CC, Chi K. Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of the therapeutic resistance in castration-resistant prostate cancer. Clin Cancer Res; Published OnlineFirst Feb 23, 2015; doi:10.1158/1078-0432.CCR-14-2666. IF 8.193

13. Zhang H, Qi S, Zhang T, Wang A, Liu R, Guo J, Wang YZ, Xu Y. miR-188-5p inhibits tumour growth and metastasis in prostate cancer by repressing LAPTM4B expression. Oncotarget. 2015 Jan 21. [Epub ahead of print]. PMID: 25714029. IF 6.67

14. Clermont PL, Lin D, Crea F, Wu R, Xue H, Wang Y, Thu KL, Lam WL, Collins CC, Wang YZ, Helgason CD. Polycomb-mediated silencing in neuroendocrine prostate cancer. Clinical Epigenetics 2015, 7:40  doi:10.1186/s13148-015-0074-4. IF 6.2.

15. El-Naggar, AM, Veinotte, CJ, Cheng H, Grunewald T, Negri, GL, Somasekharan, SP, Corkery, DP, Tirode F, Mathers J, Khan D, Kyle AH, Baker JH, Lepard NE, McKinney S, Hajee S, Bosiljcic M, Leprivier G, Tognon CE, Minchinton A, Bennewith K, Delattre O, Wang YZ, Dellaire G, Berman J, Sorensen PH. Translational activation of HIF1α by YB-1 promotes sarcoma metastasis. Cancer Cell. May 11;27(5):682-97, 2015 IF 23.89.



1. Lin D, Xue H, Wang Y, Wu R, Watahiki A, Dong X, Cheng H, Wyatt AW, Collins CC, Gout PW, Wang YZ. Next generation patient-derived prostate cancer xenograft models. Asian Journal of Andrology. 2014 May-Jun; 16(3): 407–412. PMID: 24589467. IF2.05.

2. Mo F, Wyatt AW, Sun Y, Brahmbhatt S, McConeghy BJ, Wu C, Wang YZ, Gleave ME, Volik SV, Collins CC. Systematic identification and characterization of RNA editing in low coverage sequence data from prostate tumors. PLoS ONE. 9 (7): 101431, 2014.

3. Wang K, Shrestha R, Wyatt A, Reddy A, Lehár J, Wang YZ, Lapuk A, Collins C. A Meta-Analysis Approach for Characterizing Pan-Cancer Mechanisms of Drug Sensitivity in Cell Lines PLoS ONE 9(7): e103050. 2014 

4. Lapuk AV, Volik SV, Wang YZ, Collins CC. The role of mRNA splicing in prostate cancer. Asian J Androl 16(4):515-21, 2014. PMID: 24830689

5. Luk I, Xue H, Cheng H, Lin D, Gout PW, Fazli L, Collins C, Gleave M,  Wang YZ. The BIRC6 gene as a novel target for therapy of prostate cancer: Dual targeting of Inhibitors of Apoptosis Oncotarget  2014 Aug 30;5(16):6896-908..IF 6.63

6. Xie Y, Liu S, Lu W, Yang Q, Carver BS, Li E, Wang YZ, Fazli L, Gleave M, and Chen Z. Crosstalk between nMET and SOX9/β-Catenin Correlates with Castration Resistant Prostate Cancer. Mol. Endocrinology 2014 Oct;28(10):1629-39. IF 4.746

7. Wyatt A, Mo F, Wang K, McConeghy B, Brahmbhatt S,  Jong L, Mitchell D, Johnston R, Haegert A, Li E, Liew J, Yeung J, Shrestha R, Lapuk A, McPherson A, Shukin R, Bell R, Anderson S, Bishop J, Hurtado-Coll A, Xiao H, Chinnaiyan A, Mehra R, Lin D, Wang YZ, Fazli L,  Gleave M, Volik S, and Collins C. The inter-tumor transcriptome heterogeneity of high-risk primary prostate cancer. Genome Biology 15: 426, 2014. IF 10.5

8. Eirew P, Steif A, Khattra J, Ha G, Yap D, Farahani H, Gelmon K, Chia S, Mar C, Wan A, Shumansky K, Rosner J, McPherson A, Nielsen C, Roth A, Lefebvre C, Bashashati A, deSouza C, Siu C, Edwards J, Oloumi A, Osako T, Bruna A, Sandoval J, Algara T, Greenwood W, Leung K,  Cheng H, Xue H, Wang YZ, Lin D, Mungall A, Moore R, Zhao Y, Lorette J, Nguyen L, Huntsman D, Eaves C, Hansen C, Marra M, Caldas C, Shah SP, Aparicio S. Dynamics of genomic clonal evolution in breast cancer patient xenografts at single cell resolution. Nature (2014) doi:10.1038/nature13952. IF 42.351

9. Choi SYC, Lin D, Gout PW, Collins CC, Xu Y, Wang YZ.  Lessons from patient-derived xenografts for better in vitro modeling of human cancer” Advanced Drug Delivery Reviews 2014 Dec 15;79-80C:222-237. IF 12.888

10. Svensson C, Ceder J, Gato D, Chuan YC, Pang J, Bjartell, A, Martinez R, Bott L, Helczynski L, Ulmert D, Wang YZ, Niu, YJ, Collins C, Morales A. REST mediates androgen receptor actions on gene repression and predicts early recurrence of prostate cancer. Nucleic Acids Research 42(2):999-1015, 2014. PMID: 24163104

11. Qu, S,  Wang K, Xue H, Wang Y, Wu R,  Liu C,  Gao A,  Gout PW, Collins C, Wang YZ. Enhanced anticancer activity of a combination of docetaxel and Aneustat (OMN54) in a patient-derived, advanced prostate cancer tissue xenograft model. Molecular Oncology 2014;8(2):311-22. PMID: 24388358

12. Lin D, Wyatt AW, Xue H, Wang Y, Dong X, Haegert A, Wu R, Brahmbhatt S, Mo F, Jong L, Bell RH, Anderson S, Hurtado-Cull A, Fazli L, Sharma M, Beltran H, Rubin MA, Cox ME, Gout PW, Morris J, Goldenberg L, Volik SV, Gleave ME, Collins CC, Wang YZ. High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer Research. 74(4):1272-82, 2014. PMID: 24356420

13. Chiang YT, Gout PW. Collins CC, Wang YZ. Prostate cancer metastasis-driving genes: hurdles and potential approaches in their identification. Asian Journal of Andrology 2014 Jul-Aug; 16(4): 545–548. PMID: 24589457

14. Crea F, Watahiki A, Quagliata L, Xue H, Pikor L, Parolia A, Wang Y, Lin D, Lam W, Farrar WL, Isogai T,  Morant R, Castori-Eppenberger S, Chi K, Wang YZ, Helgason C. Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer. Oncotarget 15;5(3):764-74, 2014. PMID: 24519926

15. Crea F, Clemont PL, Parolia, A, Wang YZ, Helgason CD. The non-coding transcriptome as a dynamic regulator of cancer metastasis. Cancer and Metastasis Reviews. 33: 1-16, 2014. PMID: 24346158

16. Zhang C, Kho YS, Wang Z, Chiang YT, Ng GKH, Shaw PC, Wang YZ, Qi RZ. Transmembrane and Coiled-coil Domain Family 1 Is a Novel Protein of the Endoplasmic Reticulum. PLoS ONE 9(1): e85206. doi:10.1371/journal.pone.0085206 IF 4.08

17. Chiang Y T, Wang K, Fazli L; Qi RZ, Gleave M, Collins C; Gout PW, Wang YZ. GATA2 as a potential metastasis-driving gene in prostate cancer. Oncotarget. 2014 Jan 30;5(2):451-61. PMID: 24448395. IF 6.636



19.  Nakamura H, Wang Y, Xue H, Romanish MT,  MagerDL, Helgason CD, Wang YZ. Genistein vs. ICI 182, 780: an Ally or Enemy in Metastatic Progression of Prostate Cancer. Prostate 73:1747–1760, 2013.

20. Wang K, Wang YZ, Collins CC. Chromoplexy: a new paradigm in genome remodeling and evolution.  Asian Journal of Andrology. doi: 10.1038/aja.2013.109, 2013

21. Choi SY, Collins CC, Gout PW, Wang Y. Cancer-generated lactic acid: a regulatory, immunosuppressive metabolite? J Pathol 2013 Aug; 230(4): 350-5 (Epub May 31, 2013). PMID: 23729358 (Cover Art)

22. Mendoza-Naranjo A, El-Naggar A, Wai DH, Mistry P, Lazic N, Ayala FR, da Cunha IW, Rodriguez-Viciana P, Cheng H, Tavares Guerreiro Fregnani JH, Reynolds P, Arceci RJ, Nicholson A, Triche TJ, Soares FA, Flanagan AM, Wang YZ, Strauss SJ, Sorensen PH. ERBB4 confers metastatic capacity in Ewing sarcoma. EMBO Mol Med. 2013 May 16. doi: 10.1002/emmm.201202343. PMID: 23681745

23. Yu Y, Liu L, Xie N, Xue H, Fazli L, Buttyan R, Wang YZ, Gleave M, Dong X. Expression and Function of the Progesterone Receptor in Human Prostate Stroma Provide Novel Insights to Cell Proliferation Control. J Clin Endocrinol Metab. 2013 May 10. [Epub ahead of print] PMID: 23666965

24. Watahiki A, Macfarlane RJ, Gleave ME, Crea F, Wang YZ, Helgason CD, Chi KN. Plasma miRNAs as Biomarkers to Identify Patients with Castration-Resistant Metastatic Prostate Cancer. Int J Mol Sci. 2013 Apr 10;14(4):7757-70. PMID: 23574937

25. Wyatt AW, Mo F, Wang YZ, Collins CC. The diverse heterogeneity of molecular alterations in prostate cancer identified through next-generation sequencing. Asian J Androl. 2013 May;15(3):301-8. PMID: 23503423

26. Li L, Xie H, Liang L, Gao Y, Zhang D, Fang L, Lee SO, Luo J, Chen X, Wang X, Chang LS, Yeh S, Wang YZ, He D, Chang C. Increased PrLZ-mediated androgen receptor transactivation promotes prostate cancer growth at castration-resistant stage. Carcinogenesis. 2013 Feb;34(2):257-67. 

27. Johnson DT, Luong R, Lee SH, Peng Y, Shaltouki A, Lee JT, Lin D, Wang YZ, Sun Z. Deletion of leucine zipper tumor suppressor 2 (lzts2) increases susceptibility to tumor development. J Biol Chem. 2013 Feb 8;288(6):3727-38.

28. Dong X, Lin D, Low C, Vucic EA, English JC, Yee J, Murray N, Lam WL, Ling V, Lam S, Gout PW, Wang YZ. Elevated Expression of BIRC6 Protein in Non-Small-Cell Lung Cancers is Associated with Cancer Recurrence and Chemoresistance. J Thorac Oncol. 2013 Feb;8(2):161-70.

29. Lin D, Gout PW, Wang YZ. Lessons from in-vivo models of castration-resistant prostate cancer. Curr Opin Urol. 2013 Feb 4. [Epub ahead of print]

30. Low CG, Luk IS, Lin D, Fazli L, Yang K, Xu Y, Gleave M, Gout PW, Wang YZ. BIRC6 Protein, an Inhibitor of Apoptosis: Role in Survival of Human Prostate Cancer Cells. PLoS One. 2013;8(2):e55837.



31. Becker D, Guo Y, Ghaffari M, Kumi T, Lehman M, Altamirano-Dimas M, Asrush, Furu, Wang YZ, Dedhar S, Cox M. Integrin-linked kinease (ILK) as a target for ERF-mediated invasive properties in prostate cancer models. Carcinigenesis (2012) doi: 10.1093/carcin/bgs285 First published online: October 1, 2012.

32. Duan Z,  Zou JX, Yang P, Wang YZ, Borowsky AD, Gao AC, Chen HW. Developmental and Androgenic Regulation of Chromatin Regulators EZH2 andANCCA/ATAD2 in the Prostate Via MLL Histone Methylase Complex. The Prostate 2012 Oct 4. doi:10.1002/pros.22587.

33.  Lapuk A, Wu C, Wyatt A, Mcpherson A, Mcconeghy B, Brahmbhatt S, Mo F, Zoubeidi A, Andweson S, Bell R, Haegert A, Shukin B, Wang YZ, Fazli L, Hurtado A, Jones E, Hach F, Hormozd F, Manh I, Boutros P, Bristow R, Zhao Y, Marra M, Fanjul A, Maher C, Chinnaiyan A, Rubin M, Beltran H, Sahinalp SC, Gleave M, Volik S, Collins CC. From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. The Journal of Pathology. 227(3):286-98,2012. 

34. Wu C, Wyatt AW, McPherson A, Lin D, McConeghy BJ, Mo F, Shukin R, Lapuk AV, Jones SJM, Zhao Y, Marra MA, Gleave ME, Volik SV, Wang YZ, Sahinalp SC, Collins CC. Poly-gene fusions and chromothripsis in prostate cancer. Genes, Chromosomes and Cancer 2012 Aug 25. doi:10.1002/gcc.21999.

35.  Ricke EA, Williams K, Lee YF, Couto S, Wang YZ, Hayward SW, Cunha GR, Ricke WA. Androgen hormone action in prostatic carcinogenesis: stromal androgen receptors mediate prostate cancer progression, malignant transformation, and metastasis. Carcinogenesis. doi: 10.1093/carcin/bgs153, 2012.

36.  Choi SYC, Gout PW, Collins CC, Wang YZ, Epithelial Immune cell-like transition (EIT): a proposed transdifferentiation process underlying immune-suppressive activity of epithelial cancers: Differentiation 83:293-298, 2012.

37.  Collins CC, Volik SV, Lapuk AV,  Wang Y, Gout PW, Wu C, Xue H, Cheng H, Haegert A, Bell R, Brahmbhatt S, Anderson S, Fazli1 L, Hurtado-Coll1 A, Rubin M, Demicheli F, Beltran H, Hirst M, Marra M, Gleave M, Lubin M & Wang YZ. Next Generation Sequencing of Prostate Cancer from a Patient Identifies a Deficiency of Methylthioadenine Phosphorylase (MTAP), an Exploitable Tumor Target. Molecular Cancer Therapeutics. 11 (3):775-783, 2012.

38.  Gout PW, Wang YZ. Drug sensitivity testing for personalized lung cancer therapy. J Thorac Dis 2012 Feb;4(1):17-8.



39.  Hu P, Chu GC, Zhu G, Yang H, Luthringer D, Prins G, Habib F, Wang YZ, Wang R, Chung LW, Zhau HE. Multiplexed Quantum Dot Labeling of Activated c-Met Signaling in Castration-Resistant Human Prostate Cancer. PLoS One. 6(12):e28670, 2011

40.  Beltran H, Rickman DS, Park K, Sboner A, MacDonald TY, Wang Y, Chae SS, Dheikh K, Terry S, Tagawa ST, Dhir R, Nelson J, de la Taille A, Allory Y, Gerstein MB, Perber S, Pienta K, Chinnaiyan A, Wang YZ, Collins C, Gleave M, Demichelis F, Nanus DM, Rubin MA. Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of Aurora Kinase as a Therapeutic Target. Cancer Discovery 1(6); 487–95, 2011

41.  Watahiki A, Wang Y, Morris J, Dennis K, O'Dwyer HM, Gleave M, Gout PW and Wang YZ. MicroRNAs Associated with Metastatic Prostate Cancer. PLOS ONE 6(9): e24950, 2011.

42.  Espinosa, I, Edris, B, Lee, CH, Wei Cheng, H, Gilks, CB, Wang YZ, Montgomery, K. D, Varma, S, Li, R, Marinelli, R. J, West, R. B, Nielsen, T, Beck, A. H, and van de Rijn, M. CSF1 Expression in Nongynecological Leiomyosarcoma Is Associated with Increased Tumor Angiogenesis. Am J Pathol. 179(4):2100-2107, 2011

43.  Ip, W, Wellman-Labadie, O, Tang, L, Su, M, Yu, R, Dutz, J, Wang YZ, Huang, S, Zhang, X, Huang, C, Zhou, Y. Collagen triple helix repeat containing 1 promotes melanoma cell adhesion and survival. Journal of Cutaneous Medicine and Surgery.15(2):103-110, 2011.  PubMed ID: 2147758

44.  Stany MO,  Vathipadiekal V, Ozbun L, Stone RL, Mok S, Xue H, Kagami T, Wang Y, McAlpine JN, Bowtell D,  Gout PW,  Miller DM, Gilks CB, Huntsman DG, Ellard S, Wang YZ, Vivas-Mejia P, Lopez-Berestein G, Sood AK, and Birrer MJ.  Identification of Novel Therapeutic Targets in Microdissected Clear Cell Ovarian Cancers. PLoS ONE 6(7): e21121. doi:10.1371/journal.pone.0021121. Pubmed ID: 21754983

45.  Kuchenbauer F, Mah SM, McPherson A,  Heuser M,  Argiropoulos B, Morin RD,  Berg T, Lai D, Murani, AL Hogge DE,  Ruschmann J,  Starczynowski DT, Karsan A,  O’Connor MD,  Eaves C,  Watahiki A, Wang YZ,  Aparicio SA, Ganser A,  KrauterJ, Johnnidis JB, Marra MA, Carmargo FD and Humphries RK. Comprehensive analysis of mammalian miRNA* species and their role in myeloid cells. Blood. 118(12):3350-3358, 2011

46.  Nakamura H, Wang Y,  Kurita T, Adomat  H,  Cunha  GR and  Wang YZ. Genistein increases Epidermal Growth Factor Receptor signaling and promotes tumor progression in advanced human prostate cancer.  PLoS ONE 6(5): e20034. doi:10.1371/journal.pone.0020034, 2011.  Pubmed ID:  21603581

47.  Tung WL, Wang Y, Gout PW, Liu DM, Gleave M, Wang YZ. Use of Irinotecan for Treament of Small Cell Carcinoma of the Prostate. The Prostate 71 (7): 675-681, 2011.  Pubmed ID: 20949523

48.  Terry J,  De Luca A, Leung S, Peacock G, Wang YZ,  Elloit WM, Huntsman D. Immunohistochemical expression of neurotrophic tyrosine kinase receptors 1 and 2 in lung carcinoma: potential discriminators between squamous and non-squamous subtypes. Arch Pathol Lab Med. 135(4):433-9, 2011.  Pubmed ID:  21466358

49.  Du C and Wang YZ. The immunoregulatory mechanisms of carcinoma for its survival and development. Journal of Experimental & Clinical Cancer Research. 2011, 30:12doi:10.1186/1756-9966-30-12.  Pubmed ID:  21255410

50.  Kortmann UK, McAlpine JN, Xue H, Guan J, Ha G, Tully S, Shafait S, Lau A, Cranston A, O’Connor MJ, Huntsman DG, Wang YZ, Gilks B. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts. Clin. Cancer Research. 17:783-791; 2011.  Pubmed ID:  21097693



51.  Cheng H, Clarkson PW, Gao D, Pacheco M, Wang YZ, Nielsen TO. Therapeutic Antibodies Targeting CSF1 Impede Macrophage Recruitment in a Xenograft Model of Tenosynovial Giant Cell Tumor. Sarcoma 2010 (Epub 13 Oct 2010).  Pubmed ID:  20981142.

52.  Lin D, Bayani J, Wang Y, Sadar MD, Yoshimoto M, Gout PW, Squire J, Wang YZ. Development of metastatic and non-metastatic tumor lines from a patient's prostate cancer specimen - Identification of a small subpopulation with metastatic potential in the primary tumor. The Prostate 70:1636-1644, 2010.  Pubmed ID:  20564316 

53.  Niu Y, Chang TM, Yeh S, Ma WL, Wang YZ, Chang C. Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails. Oncogene 2010. Pubmed ID:  20440270

54.  Andersen RJ, Mawji NR, Wang J, Wang G, Haile S, Myung J.K., Watt K, Tam T, Yang YC, Banuelos CA, Williams DE, McEwan I, Wang YZ, Sadar MD. Regression of castrate-recurrent prostate cancer by a small molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 17, 535-546, 2010.  Pubmed ID:  20541699

55.  Lo M, Ling V, Low C, Wang YZ, Gout PW. The Xc- cystine / glutamate antiporter as a potential therapeutic target for pancreatic cancer - Use of sulfasalazine. Current Oncology 17(3):9-16, 2010.  Pudmed ID: 19104813

56. Dong X, Guan J, English J, Flint J, Yee J, Evans K, Murray N, MacAulay C, Ng R, Gout PW, Lam W, Laskin J, Ling V, Lam S, Wang YZ. Patient-derived first generation xenografts of non-small cell lung cancers: Promising tools for predicting drug responses for personalized chemotherapy Clin. Cancer Research 16:1442-1451, 2010.  Pubmed ID: 20179238

57.  McPherson S, Hussain S, Balanathan P, Hedwards S, Niranjan B, Grant M, Chandrasiri U, Toivanen U, Wang YZ, Taylor R, Risbridger G.. Estrogen receptor beta activated apoptosis in benign hyperplasia and cancer of the prostate is androgen-independent and TNFα-mediated. Proceedings of the National Academy of Science (USA) 107(7):3123-3128, 2010.  Pubmed:  20133657

58.  Chiu H, Yong TMK, Wang J, Wang Y, Vessella RL, Ueda T, Wang YZ, and Sadar MD. Induction of Neuronal Apoptosis Inhibitory Protein Expression in Response to Androgen Deprivation in Prostate Cancer. Cancer Lett. 292:176-185, 2010.  Pubmed ID:  2044205\


59.  Gan L, Chen S, Wang Y, Watahiki A, Bohrer L, Sun Z, Wang YZ, Huang H. Inhibition of the Androgen Receptor as a Novel Mechanism of Taxol Chemotherapy in Prostate Cancer. Cancer Research 2009; 69:8386-94 (2009).  Pubmed ID:  19826044

60.  Guan J, Lo M, Dockery P, Mahon S, Karp C, Buckley A, Lam S, Gout PW, Wang YZ. The xc- cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: Use of sulfasalazine Cancer Chemotherapy and Pharmacology 2009;64:463-472. (2009).  Pubmed ID: 19104813

61.  Lo M, Wang YZ, Gout PW. Response to Savaskan NE et al. "The xc- Cystine/Glutamate Antiporter: A Potential Target for Therapy of Cancer and Other Diseases: Yet Another Cytotoxic Anticancer Approach?" J Cell Physiol 2009;220(2):533-534. 2009. 

62.  Romanish MT, Nakamura H, Lai CB, Wang YZ, Mager DL. A novel protein isoform of the multicopy human NAIP gene derives from intragenic Alu SINE promoters. PLoS One. 2009 Jun 2;4(6):e5761. 2009.  Pubmed ID:  1948840



63.  Al-Romaih K, Sadikovic B, Yoshimoto M, Wang YZ, Zielenska M, Squire JA. Decitabine induced demethylation of 5 CpG-island in GADD45A leads to apoptosis in osteosarcoma cells Neoplasia 10 p.471-480 2008. Pubmed ID:  18472964

64.  Lin D, Watahiki A, Bayani J, Zhang F, Liu L, Ling V, Sadar MD, English J, Fazli L, So A, Gout PW, Gleave M, Squire JA, Wang YZ. ASAP1, a Gene at 8q24, is Associated with Prostate Cancer Metastasis Cancer Research 68 p.4352-4359, 2008.  Pubmed ID:  18519696

65.  Lo M, Ling V, Wang YZ, Gout PW. The xc- cystine/glutamate antiporter: a mediator of pancreatic cancer growth with a role in drug resistance. British J. Cancer 99 p. 464-472, 2008.  Pubmed ID:  18648370

66.  Lo M, Wang YZ, Gout, PW. The xc- Cystine/Glutamate Antiporter: a Potential Target for Therapy of Cancer and Other Diseases. Journal of Cellular Physiology 215 p. 593-602, 2008.  Pubmed ID:  18181196

67.  Press JZ, Kenyon JA, Xue H, Miller MA, de Luca A, Miller DM, Huntsman DG, Gilks CB, McAlpine JN, Wang YZ. Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy. Gyn. Oncol. 110 p.256-264 (2008).  Pubmed ID:  18547621

68.  Ricke WA, McPherson SJ, Cunha GR, Wang YZ, Risbridger GP. Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha-signaling The FASEB Journal 22, p. 1512-1520 (2008).  Pubmed ID:  18055862



69.  Al-Romaih K, Somers GR, Bayani J, Hughes S, Prasad M, Cutz JC, Xue H, Zielenska M, Wang YZ, Squire JA. Modulation by decitabine of gene expression and growth of osteosarcoma U2OS cells in vitro and in xenografts: Identification of apoptotic genes as targets for demethylation Cancer Cell International 7:14:10 p.1186, 2007.  Pubmed ID:  17845729

70.  Doxsee D, Gout P, Kurita T, Lo M, Buckley A, Wang Y, Xue H, Karp C, Cutz JC, Cunha G, and Wang YZ. Sulfasalazine-induced cystine starvation: potential use for prostate cancer therapy. Prostate 67(2): 162-171, 2007.  Pubmed ID:  17075799

71.  Ogura Y, Ishii K, Kanda H, Kanai M, Arima K, Wang YZ, Sugimura Y. Bisphenol A induces permanent squamous change in mouseprostatic eqithelium. Differentiation 75 p. 745-756 (2007).  Pubmed ID:  17459086

72.  Ricke WA, Wang YZ, Cunha GR. Steroid hormones and carcinogenesis of the prostate: The role of estrogens. Differentiation 75: 871-882, 2007.  Pubmed ID:  17924963

73.  Verras M, Lee J, Xue H, Li TH, Wang YZ, Sun Z. The Androgen Receptor Negatively Regulates the Expression of c-Met, Implications for a Novel Mechanism of Prostate Cancer Progression Cancer Res. 67(3) : 967-975 (2007).  Pubmed ID:  17283128


74.  Cutz JC, Guan J, Bayani J, Xue H, Sutcliffe M, English J, Flint J, LeRiche J, Yee J, Squire J, Gout PW, Lam S, Wang YZ. Establishment in Severe Combined Immunodeficiency Disease Mice of Subrenal Capsule Xenografts and Transplantable Tumor Lines from a Variety of Primary Human Lung Cancers: Potential Models for Studying Tumor Progression-Related Changes. Clin. Cancer Res. 12(13): 4043-4054, 2006.  Pubmed ID:  16818704

75.  Ricke WA, Ricke EA, Simko J, Wang YZ, Harward SW, and Cunha GR. Steroid Hormones Stimulate Human Prostate Cancer Progression and Metastasis. Int. J. Cancer 118(9) : 2123-2131, 2006.  Pubmed ID:  16331600

76.  Sobel RE, Wang YZ, Sadar MD. Molecular Ananlysis and Characterization of PrEC, Commercially Available Prostate Epithelial Cells. In Vitro Cellular and Developmental Biology Animal. 42:3339 (2006).  Pubmed ID:  16618209



77.  Cunha GR, Place NJ, Baskin L, Conley A, Weldele M, Cunha TJ, Wang YZ, Cao M, Glickman SE. The Ontogeny of the Urogenital System of the Spotted Hyena. Biology of Reproduction 73 : 554-564 (2005).  Pubmed ID:  15917348

78.  Lee CH, Xue H, Sutcliffe M, Gout PW, Huntsman DG, Miller DM, Gilks CB, Wang YZ. Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models. Gynecol Oncol 96(1):48-55. (2005).   

79.  Wang Y, Xue H, Cutz JC, Bayani J, Mawji NR, Chen WG, Goetz LJ, Hayward SW, Sadar MD, Gilks CB, Gout PW, Squire JA, Cunha GR, Wang YZ. An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line. Lab Invest 85(11):1392-404. (2005).

80.  Wang YZ, Revelo MP, Sudilovsky D, Chen WG, Goetz L, Xue H, Sadar M, Shappell SB, Cunha GR and Hayward SW. Development and characterization of efficient xenograft models for benign and malignant human prostate tissue. Prostate 64, 149-159 (2005).  Pubmed ID:  15678503


81.  Cunha GR, Riche W, Thomson A, Marker PC, Risbridger G, Hayward SW, Wang YZ, Donjacour AA and Kurita T. Hormonal, Cellular, and Molecular Regulation of Normal and Neoplastic Prostatic Development. Journal of Steroid Biochemistry and Molecular Biology 92(4): 221-236 (2004).  Pubmed ID:  15663986


82.  Cunha GR, Hayward SW, Wang YZ, and Ricke WA. Stromal micro-environment in carcinogenesis of the prostate. Int J Cancer. 107:1-10 (2003).

83.  Cunha GR, Wang YZ, Place NJ, Liu W, Baskin L, Glickman SE. Urogenital System of the Spotted Hyena (Crocuta crocuta Erxleben): A Functional Histological Study. J Morphology 256 (2): 205-18 (2003).  Pubmed ID:  12635111

84.  Rubenstein NM, Cunha GR, Wang YZ, Campbell KL, Conley AJ, Catania KC, Glickman SE and Place NJ. A peniform clitoris in New World moles with and without 'ovotestes'. Reproduction 126: 713-719 (2003).  Pubmed ID:  14748690

85.  Sharma M, Li X, Wang YZ, Zarnegar M, Huang CY, Palvimo JJ, Lam B, Sun Z. hZimp10 is an androgen receptor co-activator and forms a complex with SUMO-1 at replication foci. EMBO 22 (22): 6101-6114 (2003).  Pubmed ID:  14609956

86.  Staack A, Kassis AP, Olshen A, Wang YZ, Wu D, Carroll PR, Grossfeld GD, Cunha GR, Hayward SW. Quantitation of apoptotic activity following castration in human prostatic tissue in vivo. Prostate 54: 212-219 (2003).  Pubmed ID:  12518826


87.  Cunha GR, Hayward SW, Wang YZ. Role of stroma in carcinogenesis of the prostate Differentiation 70 (9-10): 473-85 (2002).  Pubmed ID:  12492490

88.  Day KC, McCabe MT, Zhao X, Wang YZ, Phillips J, Ried T, Davis JN, KuKuruga MA, Cunha GR, Hayward SW, Day ML. Homozygous disruption of the retinoblastoma gene promotes immortalization and alters cell cycle and growth kinetics, but does not alter prostatic differentiation and morphogenesis. J Biol Chem 277 (46): 44475-44484 (2002). 

89.  Kim MJ, Bhatia-Gaur R, Banach-Petrosky WA, Desai N, Wang YZ, Hayward SW, Cunha GR, Cardiff RD, Shen MM, Abate-Shen C. Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis. Cancer Research 62:2999-3004 (2002).  Pubmed ID:  12036903


90.  Cunha GR, Wang YZ, Hayward SW, Risbridger GP. Estrogenic effects on prostatic differentiation and carcinogenesis. Reprod Fertil Dev 13:285-296 (2001).  Pubmed ID:  11800167

91.  Hayward SW, Wang YZ, Cao M, Hom YK, Zhang B, Grossfeld GD, Sudilovsky D, Cunha GR. Transformation In A Non-Tumorigenic Human Prostatic Epithelial Cell Line Cancer Res 61:8135-8142 (2001). 

92.  Kurita T, Wang YZ, Donjacour AA, Zhao C, Lydon JP, O'Malley BW, Isaacs JT, Dahiya R, Cunha G. Paracrine regulation of apoptosis by steroid hormones in the male and female reproductive system. Cell Death and Differentiation 8(2):192-200 (2001).  Pubmed ID:  11313721

93.  Phillips JL, Hayward SW, Wang YZ, Vasselli J, Pavlovich C, Padilla-Nash H, Pezullo JR, Ghadimi M, Grossfeld GD, Rivera A, Linehan WM, Cunha GR, Ried T. The Consequences of Chromosomal Aneuploidy on Gene Expression Profiles in a Cell Line Model for Prostate Carcinogenesis Cancer Res 61:8143-8149 (2001).  Pubmed ID:  11719443

94.  Risbridger G, Wang H, Young P, Kurita T, Wang YZ, Lubahn D, Gustafsson JA, Cunha G. Evidence that epithelial and mesenchymal estrogen receptor-alpha mediates effects of estrogen on prostatic epithelium. Dev Biol 229(2):432-42. (2001).  Pubmed ID:  11150243

95.  Wang YZ, Hayward SW, Cao M, Thayes KA, Cunha GR. Cell differentiation lineage in the prostate. Differentiation 68:270-279 (2001). 

96.  Wang YZ, Sudilovsky D, Zhang B, Haughney PC, Rosen MA, Wu DS, Cunha TW, Dahiya R, Cunha GR, Hayward SW. A Human Prostatic Epithelial Model of Hormonal Carcinogenesis. Cancer Res 61:6064-6072 (2001).



97.  Wang YZ, Hayward SW, Donjacour, AA, Young, P, Jacks T, Sage, J, Dahiya, R, Cardiff, R, Day, M, Cunha GR. Sex Hormone-induced Carcinogenesis in Rb-deficient Prostate Tissue. Cancer Res 60:6008-6017 (2000).  Pubmed ID:  11085521

98.  Wong YC, Wang YZ, Lee JS, Tam NN, Lee D. Changes in serum and tissue zinc levels in sex hormone-induced prostatic carcinogenesis in the noble rat. Tumour Biol 21(6):328-36. (2000).  Pubmed ID:  11006573

99.  Wang, YZ and Wong, YC. Role of insulin-like growth factor-1 (IGF-1) and vascular endothelial growth factor (VEGF) in the development of prostate cancer in the Noble rat: Evidence for stromal-epithelial interactions. Prostate 35:165-177 (1998).  Pubmed ID:  9582085

100.  Wong YC, Wang YZ, Tam NN. The prostate gland and prostate carcinogenesis. Ital J Anat Embryol 103(4 Suppl 1):237-52. (1998).



101.  Tam, NNC, Wang, YZ, Wong, YC. The influence of mesenchyme of neonatal seminal vesicle and embryonic urogenital sinus on the morphological and functional cytodifferentiation of Dunning prostatic adenocarcinoma: Roles of growth factors. Urol Oncol 3:85-93 (1997).  Pubmed ID: 21227091

102.  Wang, YZ and Wong, YC. Oncogenes and tumor suppressor genes in prostate cancer: A review. Urol Oncol 3:41-46 (1997).


Books and Chapters


Publications | Books (and Chapters)

In Press

1.  Ricke WA, Williams K, Palapattu G, Wang YZ, Cunha GR. Hormonal carcinogenesis: Roles of estrogens The Molecular Basis of Human Cancer, Vol. Part V, Humana Press (In Press).



2.  Gleave M, Cox M, Wang Y. Z., Cell biology of prostate cancer and molecular targets. In Drug Management of Prostate Cancer. (Figg, W. D.; Chau, C. H.; Small, E. J. Eds.) 2010, 1-24, DOI: 10.1007/978-1-60327-829-4_1.



3.  Waterhouse DN, Gelmon KA, Klasa R, Chi K, Huntsman D, Ramsay E, Wasan E, Edwards L, Tucker C, Zastre J, Wang YZ, Yapp D, Dragowska V, Dunn S, Dedhar S, Bally MB. Development and assessment of conventional and targeted drug combinations for use in the treatment of aggresive breast cancers. Current Cancer Drug Targets, 6, 455-489, 2006.



4.  Ricke WA, Wang YZ, Kurita T, Hayward SW, Cunha GR. Hormonal and stromal regulation of normal and neoplastic prostatic development. Developmental Biology of Neoplastic Growth, Alvaro, M-C. (Ed). Springer Verlag, New York, N.Y. pp. 183-215 (2005).



5.  Cunha GR, Hayward SW, Wang YZ, Ricke WA. Role of the stromal micro-environment in carcinogenesis of the prostate. In: Prostate and renal cancer, benign prostatic hyperplasia, erectile dysfunction and basic research: An update. Bangma CH and Newling DWW (eds), Parthenon Publishing Group, New York, pp. 155-171 (2003).



6.  Hayward SW, Wang YZ, Day ML. Rescue and Isolation of Rb-deficient Prostate Epithelium by Tissue Recombination. In: Cancer Cell Signaling: Methods and Protocols. (Terrian DM, ed) Methods in molecular Medicine, Humana Press, Totowa, NJ, Pp 17-34 (2002).

7.  Wang YZ, Cunha GR, Hayward SW. In vitro and in vivo models of prostate cancer. American Cancer Society Atlas of Clinical Oncology. Carroll PR, Grossfeld GD eds. BC Decker Inc, Hamilton, London, pp 68-81 (2002).



8.  Wong YC, Wang YZ. Growth factors and epithelial-stromal interactions in prostate cancer development. International Review of Cytology. Jeon KW ed, Academic Press, 199:65-116. (2000).


Back to Yuzho Wang's Profile

Back to Main Page